S262: THE COBALT-LYM STUDY OF CTX130: A PHASE 1 DOSE ESCALATION STUDY OF CD70-TARGETED ALLOGENEIC CRISPR-CAS9–ENGINEERED CAR T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) T-CELL MALIGNANCIES

• S. P. Iyer,
• R. A. Sica,
• P. J. Ho,
• B. Hu,
• J. Zain,
• A. Prica,
• W.-K. Weng,
• Y. H. Kim,
• M. S. Khodadoust,
• M. L Palomba,
• F. M. Foss,
• K. Tipton,
• E. L. Cullingford,
• Q. He,
• A. Sharma,
• S. M. Horwitz

Affiliations

S. P. Iyer

1 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston

R. A. Sica

2 Department of Oncology, Montefiore Medical Center, Albert Einstein Cancer Center, Bronx, United States of America

P. J. Ho

3 Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, Australia

B. Hu

4 Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, Salt Lake City

J. Zain

5 Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, United States of America

A. Prica

6 Princess Margaret Cancer Centre, Toronto, Canada

W.-K. Weng

7 Division of Blood and Marrow Transplantation and Cellular Therapy

Y. H. Kim

8 Department of Dermatology

M. S. Khodadoust

9 Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford

M. L Palomba

10 Memorial Sloan Kettering Cancer Center,, New York

F. M. Foss

11 Department of Dermatology, Yale School of Medicine, New Haven

K. Tipton

12 CRISPR Therapeutics, Cambridge, United States of America

E. L. Cullingford

12 CRISPR Therapeutics, Cambridge, United States of America

Q. He

12 CRISPR Therapeutics, Cambridge, United States of America

A. Sharma

12 CRISPR Therapeutics, Cambridge, United States of America

S. M. Horwitz

10 Memorial Sloan Kettering Cancer Center,, New York